Slide 1: Hemophilia Business Spin-Off
0 Hemophilia Business Spin-Off May 3, 2016
Slide 2: Forward-Looking Statements
1 Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements relating to the proposed spin-off of Biogen’s hemophilia business, such as the completion and timing of the proposed spin-off, its anticipated benefits, its tax treatment, an
Slide 3: Transformative Era for Biogen
2 Transformative Era for Biogen Realize full potential by allowing each company to operate independently with management teams dedicated to their respective and distinct disease areas Biogen will commit its energy and resources to the development of novel therapies for patients suffering from neu
Slide 4: Rationale for Proposed Separation
3 Rationale for Proposed Separation As a stand-alone business, a dedicated and talented management team will: • Focus on strategic priorities specific to the hemophilia patient population and market • Allocate capital and resources to continue commercializing ELOCTATE and ALPROLIX and drive innovati
Slide 5: Overview of New Hemophilia Company
4 Overview of New Hemophilia Company • Focus on the discovery and development of therapies for the treatment of hemophilia • Continue to develop and commercialize ELOCTATE and ALPROLIX, indicated for the treatment of hemophilia A and B, respectively • Additional life-cycle management initiatives exp
Slide 6: Hemophilia: Significant Market Opportunity
5 Hemophilia: Significant Market Opportunity Based on Biogen estimates, Data on File. Flags represent largest markets in respective territories. ~$7 Billion ALPROLIX is approved in the U.S., Canada, Japan, Australia, and New Zealand. Received positive CHMP opinion in the E.U. ELOCTATE is approved in
Slide 7: New Hemophilia Company: Key Marketed Products
6 • ALPROLIX and ELOCTATE represent the first meaningful improvements in hemophilia treatment in ~20 years • As of 3/31/16, ALPROLIX and ELOCTATE combined generated $640 million in revenues over the last 12 months ‒ $554 million in revenues in FY 2015 ‒ $183 million in revenues 1Q 2016 • Leading swi
Slide 8: New Hemophilia Company: Pipeline
7 New Hemophilia Company: Pipeline • Working on gene therapy for the treatment of hemophilia A and B utilizing lentiviral vectors Life-Cycle Management Initiatives Next Generation Long- Acting Factors Gene Therapy rFVIIIFc-VWF-XTEN A1 A2 A3 C1 C2 D’D3 Fc Fc • Long-acting hemophilia product candidate
Slide 9: Spin-off Details
8 Spin-off Details • Spin-off expected to be implemented by means of a distribution of 100% of the shares of a new publicly traded entity to Biogen stockholders • Spin-off is intended to be tax-free for U.S. federal income tax purposes Structure • John G. Cox, Biogen’s current Executive Vice Preside